Austin, Texas — September 10, 2025 — Leads & Copy — Oncotelic Therapeutics Inc. (OTCQB: OTLC) has chosen IBN to lead its corporate communications efforts. Oncotelic is a clinical-stage biopharmaceutical company focused on RNA-based, immunotherapy, and targeted therapeutics for cancer and underserved diseases. The company’s lead candidate, OT-101, is in a Phase 3 trial for pancreatic ductal adenocarcinoma.
IBN will leverage its investor-focused distribution network, including over 5,000 key syndication outlets, newsletters, social media channels, and wire services via InvestorWire, to boost awareness for Oncotelic Therapeutics. IBN offers a wide audience of investors, journalists, and the general public, assisting over 500 client partners with 19 years of experience.
Dr. Vuong Trieu, Chairman and CEO of Oncotelic, has filed over 500 patent applications, with 75 issued to date.
For Corporate Communications, IBN can be reached at Austin, Texas, www.InvestorBrandNetwork.com, 512.354.7000 Office, or Editor@InvestorBrandNetwork.com.
Source: Oncotelic Therapeutics Inc.
